How OpenEvidence Makes Money

“What’s especially appealing about OpenEvidence is that it’s free to use, with the startup making money solely from advertising.”

Siliconangle high

“The software is free for verified doctors to use and makes money through advertising–much like Google does. Its revenue from advertising is now coming in at an annualized rate estimated at $50 million.”

Forbes high

“The platform is free for doctors and monetized via advertising—mostly from pharmaceutical companies. Revenue is currently $50 million annualized.”

Aisq high

“OpenEvidence built a free AI-powered search engine that monetizes through pharma ads at $70-150 CPM instead of charging hospitals $500/seat like incumbent UpToDate.”

Sacra high

“OpenEvidence is making a similar bet: monetize provider usage through ad sales. While analysts state that these are primarily pharma and medical device ads, clinicians I’ve asked about their use of OpenEvidence say they only see JAMA and NEJM ads, or no ads at all.”

Substack medium

“The software is free for verified doctors to use and makes money through advertising, much like Google does. In September, OpenEvidence announced its first acquisition—the purchase of AI advertising outfit Amaro to help analyze and roll out ads faster. In July, OpenEvidence claimed it had booked ...”

Forbes high

“The company monetizes through advertising sold to pharmaceutical companies, similar to Google's search ad ...”

Linkedin medium

“By surfacing pharma and med-device ads at $70-150+ CPM to physicians at the highest-intent moment in their workflow (research), OpenEvidence monetizes ~45% of U.S. physicians making 15M clinical consultations per month for a Sacra-estimated $150M in annualized revenue as of November 2025.”

Sacra high

“The startup crossed $100 million in annualized run rate in 2025, making money from advertising even though most of the ad inventory hasn’t been unlocked yet, Nadler claims. The startup could make about $1 billion in revenue if it sold all of it, he said. Pharmaceutical and medical device companie...”

Forbes high

“OpenEvidence was one of the first AI startups to rely on advertising for revenue, which Nadler said allows faster adoption and wider use versus a paid subscription model. Companies can pay for promotions through video ads on the OpenEvidence app.”

Cnbc high

“The startup took an unconventional route to monetization, relying on advertising rather than subscriptions. Companies can promote products through video ads inside the OpenEvidence app, a model Nadler says speeds adoption and keeps the tool accessible to doctors.”

Techstartups high

“The company monetizes through pharmaceutical and medical device advertisements, achieving CPMs that can range from $70 to $1,000+, compared to $5-15 for typical social media platforms, translating to approximately $124 in average revenue per user (ARPU).”

Sacra high